Previous 10 | Next 10 |
Calyxt has changed its operating strategy to a more conventional agri-bio seed/trait model similar to those pursued by established agri-bio names like Bayer and Corteva. Calyxt is targeting new high-risk/high-reward market opportunities including winter oats, hemp, and soybeans with s...
Jefferies analyst Michael Yee predicts Biogen (BIIB) shares to rally up to $400 – 500 range if the company’s experimental Alzheimer’s disease medicine gets the regulatory approval in the U.S.Despite the doubts over its commercial prospects, the analyst expects Aducanumab ...
Image source: The Motley Fool. Cellectis SA (NASDAQ: CLLS) Q4 2020 Earnings Call Mar 5, 2021 , 8:00 a.m. ET Operator Continue reading For further details see: Cellectis SA (CLLS) Q4 2020 Earnings Call Transcript
Cellectis S.A. (CLLS) Q4 2020 Earnings Conference Call March 5, 2021 08:00 AM ET Company Participants Simon Harnest - Senior Vice President, Corporate Strategy and Finance André Choulika - Chief Executive Officer Carrie Brownstein - Chief Medical Officer Eric Dutang - Chief Financial Off...
Enrollment ongoing in 3 Cellectis-sponsored Phase 1 dose-escalation trials BALLI-01 in r/r B-ALL patients, AMELI-01 in r/r AML patients and MELANI-01 in r/r MM patients in 7 leading US clinical centers Preliminary results from our Phase 1 BALLI-01 clinical study of UCART22 i...
Cellectis (CLLS): Q4 Non-GAAP EPS of -$0.33 beats by $0.17; GAAP EPS of -$0.37 beats by $0.08.Revenue of $13.9M (+269.7% Y/Y) beats by $6.43M.Cash, cash equivalents, short-term investments, and restricted cash totaled $30.0 million as of December 31, 2020.Press Release For further details s...
NEW YORK, Feb. 25, 2021 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells (UCART), announced that it will report its financial results for the...
Cytovia Therapeutics, a biopharma developing gene-edited Natural Killer ((NK)) and Chimeric Antigen Receptor ((CAR))-NK cells derived from induced pluripotent stem cells (iPSCs), and Cellectis (CLLS) collaborate to develop TALEN gene-edited iPSC NK and CAR-NK cells. Cellectis w...
CAMBRIDGE, Mass. and NEW YORK, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Cytovia Therapeutics, Inc., a biopharmaceutical company developing allogeneic “off-the-shelf” gene-edited Natural Killer (NK) and Chimeric Antigen Receptor (CAR)-NK cells derived from induced pluripotent stem cel...
Vor Biopharma (VOR) has priced its initial public offering of ~9.83M shares at $18/share, for gross proceeds of ~$176.9M.The company originally planned to offer 8.8M shares at a price range of $16-$18.Underwriters' over-allotment is an additional 1,474,202 shares. Shares to kick-off trading t...
News, Short Squeeze, Breakout and More Instantly...
ALL represents 10% of all leukemia cases in the United States, progresses rapidly, and is typically fatal within weeks or months if left untreated 1 There is an urgent need to develop new therapies for ALL for patients who are not candidates for hematopoietic stem cell transpl...
NEW YORK, June 28, 2024 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, held today a shareholders general meeting at 2:30 p.m. CET at the Biopark...
NEW YORK, June 20, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today the publication of a...